Consequently, sCLU’s involvement is observed to trigger specific responses in HCC cells towards sorafenib/AKT, which include the development of chemotherapy resistance, tumor metastasis, and enhanced tumor growth. This evidence concerns the gene AKT1 and hepatocellular carcinoma.